Triple-negative Breast Cancer Clinical Trial
Official title:
Phase Ⅱ Study of Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer
The purpose of this study is to assess the efficacy and safety of patients who receive apatinib plus capecitabine or capecitabine for maintenance therapy of patients with with advanced triple-negative breast cancer
Triple-negative breast cancer (TNBC) has the characteristics of early onset, high malignancy,
less treatment, and resistance to treatment. Advanced patients have shorter survival than
other subtypes. Maintenance therapy after combination chemotherapy can prolong the disease
control time in patients with advanced TNBC. How to prolong the disease control time of
patients with advanced TNBC without affecting the quality of life has become the focus of
current research.
Anti-angiogenic drugs are currently one of the few targeted therapies that have achieved some
efficacy in TNBC. Apatinib, a targeted inhibitor of VEGF receptor 2 (VEGFR2), shows
significant antitumor activity in the patients with breast cancer. The results of this study
will help explore the new treatment of small molecule anti-angiogenic drugs for TNBC
maintenance therapy, and provide some new ideas for improving individualized treatment
options for patients with advanced TNBC.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03639948 -
Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer
|
Phase 2 | |
Withdrawn |
NCT02427581 -
Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
|
Phase 1 | |
Completed |
NCT04584112 -
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
|
Phase 1 | |
Completed |
NCT01881230 -
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
|
Phase 2/Phase 3 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Terminated |
NCT01918306 -
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04914390 -
A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer
|
Phase 2 | |
Completed |
NCT03154749 -
DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
|
Phase 2 | |
Completed |
NCT04504916 -
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)
|
Phase 2 | |
Completed |
NCT03345485 -
Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04582955 -
Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy
|
N/A | |
Terminated |
NCT04099277 -
A Study of LY3435151 in Participants With Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT01695057 -
Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer
|
N/A | |
Terminated |
NCT01234532 -
Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery
|
Phase 2 | |
Recruiting |
NCT03805399 -
FUSCC Refractory TNBC Umbrella (FUTURE)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04129996 -
A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)
|
Phase 2 | |
Terminated |
NCT03621982 -
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05336721 -
A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC
|
Phase 2 | |
Terminated |
NCT03674827 -
Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC
|
Phase 1 | |
Completed |
NCT04177108 -
A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
|
Phase 3 |